Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor

[Image: see text] Boceprevir (SCH 503034), 1, a novel HCV NS3 serine protease inhibitor discovered in our laboratories, is currently undergoing phase III clinical trials. Detailed investigations toward a second generation protease inhibitor culminated in the discovery of narlaprevir (SCH 900518), 37...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Arasappan, Ashok, Bennett, Frank, Bogen, Stephane L., Venkatraman, Srikanth, Blackman, Melissa, Chen, Kevin X., Hendrata, Siska, Huang, Yuhua, Huelgas, Regina M., Nair, Latha, Padilla, Angela I., Pan, Weidong, Pike, Russell, Pinto, Patrick, Ruan, Sumei, Sannigrahi, Mousumi, Velazquez, Francisco, Vibulbhan, Bancha, Wu, Wanli, Yang, Weiying, Saksena, Anil K., Girijavallabhan, Viyyoor, Shih, Neng-Yang, Kong, Jianshe, Meng, Tao, Jin, Yan, Wong, Jesse, McNamara, Paul, Prongay, Andrew, Madison, Vincent, Piwinski, John J., Cheng, Kuo-Chi, Morrison, Richard, Malcolm, Bruce, Tong, Xiao, Ralston, Robert, Njoroge, F. George
Formato: Artigo
Idioma:Inglês
Publicado em: American Chemical Society 2010
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007962/
https://ncbi.nlm.nih.gov/pubmed/24900178
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml9000276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados